RORα is a previously unrecognized central regulator of the cardiac myogenic transcriptome and Adra1a in cardiomyocytes, with potential implications for cardiomyocyte injury and circadian biology.
Preclinical data warrant caution against clinical translation; leaves open RORα as a target in human cardiomyocyte injury and circadian biology.
Collectively these findings position RORα as a previously unrecognized central regulator of the cardiac myogenic transcriptome and the first recognized transcriptional regulator of Adra1a in cardiomyocytes. Future studies will probe the contribution of RORα-mediated transcriptional regulation of Adra1a to both the response to cardiomyocyte injury and maintenance of circadian biology.
No takes yet. Share an insight, caveat, or question.
Nagalingam et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: